Iguratimod structure
Iguratimod
In August 2011, China’s State FDA approved Simcere Pharmaceutical
Group’s new drug application for iguratimod (T-614), a disease modifying
anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis
(RA). Preclinical in vivo studies indicated that iguratimod was effective
in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg)
in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.
Find 32 Related Holders
Hunan Warrant Chiral Pharmaceutical Co., Ltd.
China
China
API Registration Country
API Inactive
-
Founded in:
2014-03-17 -
Country:
China -
Address:
No. 139, Tongguan Avenue, Tongguan Circular Economy Industrial Base, Wangcheng Economic and Technological Development Zone, Changsha -
Tax NO.:
91430122095731067R -
Registered Funds:
300 million yuan -
Website:
-
Email:
Shandong Lukang Pharmaceutical Co., Ltd.
China
China
API Registration Country
API Inactive
-
Founded in:
1993-02-15 -
Country:
China -
Address:
No. 88, Deyuan Road, Jining High-tech Zone, Shandong Province -
Tax NO.:
913700001659297311 -
Registered Funds:
880.229735 yuan -
Website:
-
Email:
Recommended Suppliers of Iguratimod
-
ROYAL PHARM
CN1 YR
Contact Supplier -
Henan Lihao Chem Plant Limited
CN1 YR
Contact Supplier -
Alicorn Pharmaceutical
CN1 YR
Contact Supplier -
Wuhan Pnq Int Trade Co., Ltd
CN1 YR
Contact Supplier -
BOC Sciences
US1 YR
Contact Supplier